keyword
MENU ▼
Read by QxMD icon Read
search

Drug resistant depression

keyword
https://www.readbyqxmd.com/read/29774621/increase-of-frontal-cerebral-blood-volume-during-transcranial-magnetic-stimulation-in-depression-is-related-to-treatment-effectiveness-a-pilot-study-with-near-infrared-spectroscopy
#1
Toshikazu Shinba, Nobutoshi Kariya, Saori Matsuda, Hanae Matsuda, Yusuke Obara
AIM: Alterations of cerebral blood flow have been reported in studies of depression treated by transcranial magnetic stimulation (TMS). However, the relationship between these changes in activity during stimulation and the effectiveness of TMS is not known. The aim of this study was to determine whether changes in frontal cerebral blood volume measured as frontal hemoglobin concentration (fHbC) during TMS are correlated with clinical outcomes of treatment. METHODS: Fifteen drug-resistant patients with depression underwent a standard treatment regimen of TMS to the left dorsolateral prefrontal cortex...
May 18, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29764522/treatment-resistant-depression-and-peripheral-c-reactive-protein
#2
Samuel R Chamberlain, Jonathan Cavanagh, Peter de Boer, Valeria Mondelli, Declan N C Jones, Wayne C Drevets, Philip J Cowen, Neil A Harrison, Linda Pointon, Carmine M Pariante, Edward T Bullmore
BACKGROUND: C-reactive protein (CRP) is a candidate biomarker for major depressive disorder (MDD), but it is unclear how peripheral CRP levels relate to the heterogeneous clinical phenotypes of the disorder.AimTo explore CRP in MDD and its phenotypic associations. METHOD: We recruited 102 treatment-resistant patients with MDD currently experiencing depression, 48 treatment-responsive patients with MDD not currently experiencing depression, 48 patients with depression who were not receiving medication and 54 healthy volunteers...
May 16, 2018: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/29761488/psychological-therapies-for-treatment-resistant-depression-in-adults
#3
REVIEW
Sharea Ijaz, Philippa Davies, Catherine J Williams, David Kessler, Glyn Lewis, Nicola Wiles
BACKGROUND: Antidepressants are a first-line treatment for adults with moderate to severe major depression. However, many people prescribed antidepressants for depression don't respond fully to such medication, and little evidence is available to inform the most appropriate 'next step' treatment for such patients, who may be referred to as having treatment-resistant depression (TRD). National Institute for Health and Care Excellence (NICE) guidance suggests that the 'next step' for those who do not respond to antidepressants may include a change in the dose or type of antidepressant medication, the addition of another medication, or the start of psychotherapy...
May 14, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29745343/indazoles-derivatives-promising-anti-tumor-agents
#4
Yichao Wan, Shengzhuo He, Wei Li, Zilong Tang
Currently, cancer continues being a dramatically increasing and serious threat to public health. Although many anti-tumor agents have been developed in recent years, the survival rate of patients is not satisfactory. The poor prognosis of cancer patients is closely related to the occurrence of drug resistance. Therefore, it is urgent to develop new anti-tumor agents to make up for the deficiency. Indazoles is an important class of heterocyclic compounds possessing a variety of biological activities, such as anti-tumor, anti-bacterial, anti-inflammatory, anti-depressant and anti-hypertensive...
May 9, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29740014/different-patterns-of-epileptiform-like-activity-are-generated-in-the-sclerotic-hippocampus-from-patients-with-drug-resistant-temporal-lobe-epilepsy
#5
Selvin Z Reyes-Garcia, Carla A Scorza, Noemi S Araújo, Nancy N Ortiz-Villatoro, Anaclara Prada Jardim, Ricardo Centeno, Elza Márcia Targas Yacubian, Jean Faber, Esper A Cavalheiro
Human hippocampal slice preparations from patients with temporal lobe epilepsy (TLE) associated with hippocampal sclerosis (HS) are excellent material for the characterization of epileptiform-like activity. However, it is still unknown if hippocampal regions as cornu Ammonis (CA) 1, CA3 and CA4, generate population epileptiform-like activity. Here, we investigated epileptiform activities of the subiculum, CA1, CA2, CA3, CA4 (induced by elevation of extracellular potassium concentration) and the dentate gyrus (induced with hilar stimulation and elevation of potassium concentration) from sclerotic hippocampi of patients with drug-resistant TLE...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29736744/antidepressant-efficacy-and-tolerability-of-ketamine-and-esketamine-a-critical-review
#6
REVIEW
P Molero, J A Ramos-Quiroga, R Martin-Santos, E Calvo-Sánchez, L Gutiérrez-Rojas, J J Meana
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype containing the NMDA receptor subunit 2B (NR2B), inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase, increased expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrKB), and activation of the mammalian target of rapamycin (mTOR) signaling pathway, alongside other independent actions attributed to the ketamine metabolism to R-hydroxynorketamine (R-HNK)...
May 7, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29736027/antidepressive-effects-of-targeting-elk-1-signal-transduction
#7
Kallia Apazoglou, Séverine Farley, Victor Gorgievski, Raoul Belzeaux, Juan Pablo Lopez, Julien Grenier, El Chérif Ibrahim, Marie-Anne El Khoury, Yiu C Tse, Raphaele Mongredien, Alexandre Barbé, Carlos E A de Macedo, Wojciech Jaworski, Ariane Bochereau, Alejandro Orrico, Elsa Isingrini, Chloé Guinaudie, Lenka Mikasova, Franck Louis, Sophie Gautron, Laurent Groc, Charbel Massaad, Ferah Yildirim, Vincent Vialou, Sylvie Dumas, Fabio Marti, Naguib Mechawar, Elise Morice, Tak P Wong, Jocelyne Caboche, Gustavo Turecki, Bruno Giros, Eleni T Tzavara
Depression, a devastating psychiatric disorder, is a leading cause of disability worldwide. Current antidepressants address specific symptoms of the disease, but there is vast room for improvement 1 . In this respect, new compounds that act beyond classical antidepressants to target signal transduction pathways governing synaptic plasticity and cellular resilience are highly warranted2-4 . The extracellular signal-regulated kinase (ERK) pathway is implicated in mood regulation5-7 , but its pleiotropic functions and lack of target specificity prohibit optimal drug development...
May 7, 2018: Nature Medicine
https://www.readbyqxmd.com/read/29726758/pharmacotherapy-for-the-treatment-of-depression-in-patients-with-alzheimer-s-disease-a-treatment-resistant-depressive-disorder
#8
Madia Lozupone, Maddalena La Montagna, Francesca D'Urso, Carla Piccininni, Rodolfo Sardone, Vittorio Dibello, Gianluigi Giannelli, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Nicola Quaranta, Davide Seripa, Antonello Bellomo, Giancarlo Logroscino, Francesco Panza
Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. Areas covered: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs)...
May 4, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29724486/computer-based-monitoring-and-evaluation-of-epilepsy-related-health-variables-and-their-impact-on-treatment-decision
#9
Melanie Bergmann, Manuela Prieschl, Gerald Walser, Gerhard Luef, Gerhard Rumpold, Iris Unterberger
OBJECTIVE: This study aimed to determine the effectiveness of electronic patient-reported outcomes (ePROs) with focus on epilepsy-specific quality of life, psychiatric and psychosocial burden, drug side effects, and patient satisfaction via the Computer-based Health Evaluation System (CHES) and to evaluate their impact on treatment regimen. METHODS: Forty consecutive patients with drug-resistant focal epilepsy undergoing prolonged video-electroencephalography (EEG) monitoring at the Department of Neurology, Innsbruck Medical University were included and randomized to an intervention group (questionnaire results accessible to the physicians) and a control group (questionnaire results inaccessible to the physicians)...
April 30, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29724381/pulmonary-deposition-of-fluticasone-propionate-formoterol-in-healthy-volunteers-asthmatics-and-copd-patients-with-a-novel-breath-triggered-inhaler
#10
Dominik Kappeler, Knut Sommerer, Claudius Kietzig, Bärbel Huber, Jo Woodward, Mark Lomax, Prashant Dalvi
INTRODUCTION: A combination of fluticasone propionate/formoterol fumarate (FP/FORM) has been incorporated within a novel, breath-triggered device, named K-haler® . This low resistance device requires a gentle inspiratory effort to actuate it, triggering at an inspiratory flow rate of approximately 30 L/min; thus avoiding the need for coordination of inhalation with manual canister depression. The aim of the study was to evaluate total and regional pulmonary deposition of FP/FORM when administered via the K-haler device...
May 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29718333/neural-response-after-a-single-ect-session-during-retrieval-of-emotional-self-referent-words-in-depression-a-randomized-sham-controlled-fmri-study
#11
Kamilla W Miskowiak, Julian Macoveanu, Martin B Jørgensen, Mette M Støttrup, Caroline V Ott, Hans M Jensen, Anders Jørgensen, J Harmer, Olaf B Paulson, Lars V Kessing, Hartwig R Siebner
Background: Negative neurocognitive bias is a core feature of depression that is reversed by antidepressant drug treatment. However, it is unclear whether modulation of neurocognitive bias is a common mechanism of distinct biological treatments. This randomized controlled functional magnetic resonance imaging study explored the effects of a single electroconvulsive therapy session on self-referent emotional processing. Methods: Twenty-nine patients with treatment-resistant major depressive disorder were randomized to one active or sham electroconvulsive therapy session at the beginning of their electroconvulsive therapy course in a double-blind, between-groups design...
March 1, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29718262/ketamine-effects-on-eeg-during-therapy-of-treatment-resistant-generalized-anxiety-and-social-anxiety
#12
Shabah Mohammad Shadli, Tame Kawe, Daniel Martin, Neil McNaughton, Shona Neehoff, Paul Glue
Background: Ketamine is swiftly effective in a range of neurotic disorders that are resistant to conventional antidepressant and anxiolytic drugs. The neural basis for its therapeutic action is unknown. Here we report the effects of ketamine on the EEG of patients with treatment-resistant generalized anxiety and social anxiety disorders. Methods: Twelve patients with refractory DSM-IV generalized anxiety disorder and/or social anxiety disorder provided EEG during 10 minutes of relaxation before and 2 hours after receiving double-blind drug administration...
April 24, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29715359/chronic-hepatitis-b-infection-a-review
#13
REVIEW
Lydia S Y Tang, Emily Covert, Eleanor Wilson, Shyam Kottilil
Importance: More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer. Observations: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis...
May 1, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29709878/genetic-polymorphisms-of-the-5ht-receptors-are-not-related-with-depression-in-temporal-lobe-epilepsy-caused-by-hippocampal-sclerosis
#14
Silvia Vincentiis, Juliana Alcantara, Patricia Rzezak, Daniel S Kerr, Wagner F Gattaz, Helio van der Linden, Bernardo Dos Santos, Sebastiao E Melo-Souza, Francisco Arruda, Paulo Ragazzo, Tiffany Chaim-Avancini, Mauricio H Serpa, Fernando Fernandes, Ricardo A Moreno, Geraldo Busatto, Ruda Alessi, Renata Demarque, Kette D Valente
BACKGROUND: Temporal lobe epilepsy caused by hippocampal sclerosis (TLE-HS) is the most frequent form of drug-resistant epilepsy in adults. Mood disorders are the most frequent psychiatric comorbidities observed in these patients. Common pathophysiological mechanisms of epilepsy and psychiatric comorbidities include abnormalities in the serotonin pathway. The primary goal of this study was to determine the possible association between polymorphisms of genes encoding the serotonin receptors 5HT1A (rs6295), 5HT1B (rs6296), and 5HT2C (rs6318) and the presence of mood disorders in patients with TLE-HS...
April 27, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29708958/analysis-of-growth-hormone-levels-in-the-blood-of-patients-with-drug%C3%A2-resistant-depression
#15
Żanna Pastuszak, Adam Stępień, Grzegorz Kamiński, Elżbieta Deptuła-Krawczyk, Lidia Trawińska, Agata Kryszak
No abstract text is available yet for this article.
April 30, 2018: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29705022/comorbid-thyroid-disease-in-patients-with-major-depressive-disorder-results-from-the-european-group-for-the-study-of-resistant-depression-gsrd
#16
Gernot Fugger, Markus Dold, Lucie Bartova, Alexander Kautzky, Daniel Souery, Julien Mendlewicz, Alessandro Serretti, Joseph Zohar, Stuart Montgomery, Richard Frey, Siegfried Kasper
This multicenter study of the European Group for the Study of Resistant Depression (GSRD) aimed to explore the association between major depressive disorder (MDD) and comorbid thyroid disease. A total number of 1410 patients` characteristics in terms of demographic and clinical information were compared between MDD subjects with and without concurrent thyroid disease using descriptive statistics, analyses of covariance (ANCOVA) and binary logistic regression analyses. We determined a point prevalence rate for comorbid hypothyroidism of 13...
April 25, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29702232/biopharmaceutical-evaluation-of-surface-active-ophthalmic-excipients-using-in-vitro-and-ex-vivo-corneal-models
#17
Marina Juretić, Biserka Cetina-Čižmek, Jelena Filipović-Grčić, Anita Hafner, Jasmina Lovrić, Ivan Pepić
The objective of this study was to systematically investigate the effects of surface active ophthalmic excipients on the corneal permeation of ophthalmic drugs using in vitro (HCE-T cell-based model) and ex vivo (freshly excised porcine cornea) models. The permeation of four ophthalmic drugs (i.e., timolol maleate, chloramphenicol, diclofenac sodium and dexamethasone) across in vitro and ex vivo corneal models was evaluated in the absence and presence of four commonly used surface active ophthalmic excipients (i...
April 24, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29699723/delayed-increase-of-thrombocyte-levels-after-a-single-sub-anesthetic-dose-of-ketamine-a-randomized-trial
#18
Lejla Colic, Marie Woelfer, Merima Colic, Anna Linda Leutritz, Thomas Liebe, Luisa Fensky, Zumrut Duygu Sen, Meng Li, Juliane Hoffmann, Moritz A Kretzschmar, Berend Isermann, Martin Walter
Recently, ketamine has been investigated as a potential antidepressant option for treatment resistant depression. Unlike traditional drugs, it yields immediate effects, most likely via increased glutamatergic transmission and synaptic plasticity. However, ketamine administration in humans is systemic and its long-term impact on blood parameters has not yet been described in clinical studies. Here we investigated potential sustained effects of ketamine administration (0.5 mg/kg ketamine racemate) on hematological and biochemical values in plasma and serum in a randomized double-blinded study...
April 23, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29686169/risk-factors-for-multidrug-resistant-tuberculosis
#19
Cleopas Martin Rumende
In 2015, 10.4 million people developed tuberculosis (TB) and 580,000 amongst them suffered from multidrug-resistant TB (MDR-TB). From those 580,000 cases of MDR-TB, only 125,000 were detected and reported. A total of 111,000 people began to receive MDR-TB treatment in 2014 while 190,000 MDR-TB patients were estimated to have died, largely due to lack of access to effective treatment. The mechanism of drug resistance can be caused by genetic factors, factors related to previous treatment and other factors such as comorbidity with diabetes mellitus...
January 2018: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/29628065/modulating-emotion-perception-opposing-effects-of-inhibitory-and-excitatory-prefrontal-cortex-stimulation
#20
Swantje Notzon, Christian Steinberg, Peter Zwanzger, Markus Junghöfer
BACKGROUND: Excitatory repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (dlPFC) is approved by the U.S. Food and Drug Administration for the treatment of adult patients with treatment-resistant major depressive disorder (MDD). This stimulation is supposed to restore excitability of prefrontal cortex regions that exhibit diminished regulation of emotion-generative systems in MDD. Based on the valence lateralization hypothesis, inhibitory rTMS of the right dlPFC has also been applied in MDD...
April 2018: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
keyword
keyword
12250
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"